Observational studyBMC ophthalmology2026
Descemet membrane endothelial keratoplasty in patients after radiation therapy for uveal melanoma.
Observational study in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the visual outcomes and postoperative complications after Descemet membrane endothelial keratoplasty (DMEK) in patients after radiation therapy for uveal melanoma.
methodsIn this retrospective observational study, 9 eyes of 9 patients after radiation therapy for uveal melanoma who received DMEK surgery at the Charité – Universitätsmedizin Berlin were included. Preoperative patients` characteristics were analyzed. Postoperative results including visual acuity and endothelial cell density and complications were evaluated.
resultsBest-corrected visual acuity improved 3, 12 and 24 months after DMEK (preoperative: 0.88 ± 0.47 logMAR, after 3 months: 0.52 ± 0.30 (p = 0.049), after 12 months: 0.60 ± 0.35 logMAR (p = 0.66), after 24 months: 0.60 ± 0.45 logMAR (p = 0.357)) compared to preoperatively. Endothelial cell density decreased 3 and 12 months after DMEK (preoperative: 2327 ± 242 cells/mm2, after 3 months: 1831 ± 384 cells/mm2 (p = 0.068), after 12 months: 1350 ± 996 cells/mm2 (p = 0.180)). Re-bubbling was performed in 55.6% of eyes after DMEK. One patient developed a postoperative macular edema, and another one a distant metastasis of the liver 20 years after last tumor treatment. Two-year-incidence of graft rejection was 0%, of graft failure 25.0% (95%KI -17.5%, 67.5%), of IOP-elevation 55.6% (95% KI 12.1%, 99.1%) and of post-DMEK glaucoma 16.7% (95%KI -13.1%, 46.5%).
conclusionsOur results confirm that DMEK surgery is feasible and improves the visual acuity in patients with local control of uveal melanoma after radiation therapy. However, the complications rate is high - including graft failure, postoperative IOP elevation and post-DMEK glaucoma - and complications of the radiation treatment limit the achievable visual acuity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.